Advanced insulin pumps cut blood sugar swings in young diabetics
A new study shows that automated insulin pumps significantly reduce dangerous glucose fluctuations in preschoolers with Type 1 diabetes, compared to manual injections. The finding matters because erratic blood sugar in early childhood may harm brain development—making device choice a potential lever for long-term health outcomes and reduced healthcare costs.
Originaltitel: Beyond TIR: the impact of technology on glucose variability in a cohort of preschool children with T1D.
Pump- och sensorsystem reducerar blodglukossvängningarna betydligt mer än injektioner hos små barn med typ 1-diabetes — en upptäckt som påverkar köpbeslut inom regionvård och teknikleverantörer. Italiensk forskargrupp följde 54 barn under sex år under ett år. Gruppen jämförde tre insulintillförselmetoder: injektioner med glukossensor (MDI+CGM, 31 barn), sensoröverstyrd pump (SAP, 12 barn) och helt automatiserad loop-system (AHCL, 11 barn). AHCL minskade höga blodglukosvärdor (>180 och >250 mg/dL) från månad sex och framåt jämfört med injektioner. Även glukossvängningarnas amplitud (MAGE) och högt-blodglukos-index (HBGI) förbättrades signifikant med automatiserad loop. För regionala inköpare är detta relevantgrund för att rekommendera pump framför injektioner redan vid diagnos, då hjärnutvecklingen i liten ålder är känslig för glukosfluktuationer. Kommersialisering av automatiserad teknik accelereras.
BACKGROUND: In preschool children, high glucose levels and glucose fluctuations have been associated with detrimental effects on the developing brain. Although many studies show how Advanced Hybrid Closed Loop (AHCL) systems enhance common metrics, the evidence regarding their effect on glucose variability in this age group remains limited. AIM: To compare the effectiveness of Multiple Daily Injection (MDI) plus Continuous Glucose Monitoring (CGM) versus Sensor Augmented Pump (SAP) and AHCL in preschool children with T1D, focusing on glucose variability. METHODS: A retrospective, one-year, observational, real-world study was performed involving 54 children with Type 1 Diabetes (T1D) < 6 years of age. CGM data were downloaded and entered into GlyCalculator3 software at three-month intervals (t3, t6, t9, t12). RESULTS: Patients were categorized into three groups according to the insulin delivery system used: MDI + CGM (n = 31), SAP (n = 12) and AHCL (n = 11). AHCL showed significantly greater TIR compared to MDI at all timepoints (p < 0.05). Similarly, TAR > 180 mg/dL (p < 0.05 at t6, t9, t12) and TAR > 250 mg/dL (p < 0.05 at t3, t6, t9, t12) were significantly reduced in the AHCL group versus MDI + CGM group. Both mean and median sensor glucose (SG) levels showed significant improvement in pump users. Although HbA1c did not reach statistical significance, the Glucose Management Indicator (GMI) was significantly lower in the AHCL group from t6 onwards. The high blood glucose index (HBGI) significantly improved in AHCL group showing statistical significance from t6 and persisting throughout the observation period (p < 0.05 at t6, t9, t12). The multivariable linear regression analysis indicated that AHCL and SAP were associated with lower GMI, HBGI and Mean Amplitude of Glucose Excursion (MAGE) than MDI + CGM. CONCLUSION: Both AHCL and SAP systems significantly reduce glucose variability in preschool children with T1D and should be preferred over MDI + CGM in this age group. AHCL outperformed across standard glycemic metrics, supporting its use as the optimal therapeutic strategy.